A Real-World Study of Clinical Adoption, Treatment Patterns and Tolerability of Adjuvant Ribociclib in HR+/HER2- Early Breast Cancer Patients
Clinical trial NCT07710716 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT07710716
- Sponsor
- Novartis Pharmaceuticals
- Status
- ACTIVE_NOT_RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2026-04-09
- Primary completion
- 2026-09-30
- Enrollment
- 3000
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.